The global liver cancer diagnostics market reached a valuation of around US$ 11.73 Bn in 2022 and is slated to accelerate at a CAGR of 8.2% to top US$ 26 Bn by 2032. This noteworthy jump in market size is because of growing investments in research programs in regions like North America & Europe.
Fact.MR, in its latest business intelligence study, depicts the nuts and bolts of the global Liver Cancer Diagnosticss market. The report presents detailed information regarding the drivers, restraints, opportunities and trends affecting market growth.
Each segment along with its sub-segment is analyzed in terms of value and volume. Further, the report elaborates the market behavior of each vendor operating in the Liver Cancer Diagnosticss market.
Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=73
Key findings of the Liver Cancer Diagnosticss market study:
- Regional breakdown of the Liver Cancer Diagnosticss market based on predefined taxonomy.
- Innovative manufacturing processes implemented by Liver Cancer Diagnosticss vendors in detail.
- Region-wise and country-wise fragmentation of the Liver Cancer Diagnosticss market to grasp the revenue, and growth outlook in these areas.
- Changing preferences among consumers across various regions and countries.
- Factors (Positive and Negative) impacting the growth of the global Liver Cancer Diagnosticss market.
Competitive Landscape
Top manufacturers of liver cancer diagnosis instruments are investing in research & development that would aid in diagnosis and treatment more effectively and efficiently.
- In August 2021, Illumina, Inc. announced the acquisition of GRAIL, a healthcare company focused on life-saving early detection of multiple cancers but will hold GRAIL as a separate company during the European Commission’s ongoing regulatory review.
- In September 2021, India-based BDR Pharma announced the launch of the generic cancer drug called Cabozantinib. The drug is said to be helpful in the treatment of hepatocellular carcinoma and other types of cancers.
- In June 2022, Adaptimmune and Genetech announced a collaboration through which they would be commercializing allogeneic T-cell therapies to treat various cancers. This collaboration could generate around US$ 3 Bn for the companies involved.
- In August 2021, 111, a digital health platform, entered into a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals Co. to develop a virtual platform for liver cancer-affected individuals. The platform would provide patients access to online doctor consultations and medicines.
Key Segments in Liver Cancer Diagnostics Industry Research
- By Test Type :
- AFP Tests
- LFTs
- Biopsy
- Others
- By End User :
- Hospital-associated Labs
- Independent Diagnostic Laboratories
- Cancer Research Institutes
- Others
- By Region :
- North America
- Europe
- Asia Pacific
- The Middle East & Africa
- Latin America
Get Full Access of Complete Report:
https://www.factmr.com/checkout/73
Queries addressed in the Liver Cancer Diagnosticss market report:
- Why are the Liver Cancer Diagnosticss market players targeting region for increased product sales?
- What patented technologies are the players utilizing in the global Liver Cancer Diagnosticss market?
- Which regions are displaying the fastest growth in the Liver Cancer Diagnosticss market?
- What are the underlying micro- macroeconomic factors affecting the global Liver Cancer Diagnosticss market?
Why choose Fact.MR?
Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients’ requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.
Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: [email protected]